Stryker Recall Again / Stryker LFIT V40 femoral head / #stryker / #hiprecall / #revisionsurgery

If you have had hip surgery and believe you may have a Stryker hip implant product, contact The Ahearne law Firm for a free consultation and case evaluation. Call nationwide at (845) 763-4100.

On August 29, 2016 Stryker issued a new recall of the Stryker LFIT V40 femoral head hip implant component. The recall is directed to surgeons encouraging doctors to follow up with patients. Patients who have had problems with their hips and received an implant containing the Stryker LFIT should contact both their doctors and an attorney for further information. Those patients may require revision surgery and as a consequence, may also be eligible for compensation to pay for medical bills and the pain and suffering caused by the defective implant.

The Stryker LFIT V40 femoral head is used in the Stryker Accolade TMZF and Accolade 2, and the Citation and Meridian stems. The Stryker LFIT has an increased risk of metallosis, which occurs when cobalt and chromium from the replacement device are absorbed by the tissue surrounding the implant and enter the patient’s blood stream. The LFIT also allegedly has an increased risk of spontaneous dislocation or dissociation.

Patients may suffer early symptoms that warn them of potential failure of the device such as pain, swelling, and reduced mobility, and there are also cases of spontaneous dislocation, in which a minor movement causes the head to snap off the device leading to a medical emergency.

Thousands of lawsuits against the maker of the Stryker LFIT V40 femoral head are expected as a result of the recall. Issues associated with the Stryker LFIT V40 femoral head reportedly result in failure of the device, requiring patients to undergo revision surgery to fix the problem. Previously, Stryker’s Rejuvenate and AGB implants were recalled in 2012 after reports indicated an increased risk of failure. Faced with thousands of lawsuits filed nationwide, Stryker settled in a consolidated case for $1.4 billion.